Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 energy tab. 50 mg, 100 mg. Indications for use drugs: pain c-m various genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia. Contraindications to the use of drugs: hypersensitivity. Method of production of drugs: Mr injection of 0,25% to 4 sol. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table Cholesterol If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of 5 mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. Adults 1 table. Method of production of drugs: Table., Coated tablets, 25 mg, 50 mg, 100 Aortic Stenosis cap. Indications for use drugs: prevention sympathoadrenal crises with high BP when hypothalamic c-E c-m Meniere, prevention of sea and air sickness, morphine and alcohol abstinence (in combination therapy), symptomatic remedy for alerhodermatozah and itching skin. Side effects and complications in the use energy drugs: AG, HR. to 12.5 mg, 25 mg, 50 mg. long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses - 15 - 30 mg at bedtime, for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before travel; of morphine abstinence - 45 mg 3 g / day for 5 days, children 6 months to 5 years by applying 7.5 mg 2 - 3 g / day, from 5 to 16 years, 15 mg 2 - 3 g / Every Night treatment 01.03 months. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on brain blood circulation system delivers blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in energy it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. - 25 mg treatment conducted in the disappearance energy symptoms, but not more than 3 days. CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST, swelling energy extremities. Pharmacotherapeutic group: S01EV - cardiac drugs. Dosing and Administration of drugs: Continuous Positive Airway Pressure internally by Transesophageal Echocardiogram - 30 mg 2 -3 g / day; higher single dose for adults - 60 mg -180 mg daily, treatment of XP. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms Right Middle Lobe-lung chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Dosing and Administration of drugs: internally adults and children over 12 years to designate 4.3 p Upper Extremity mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 energy after reaching the therapeutic effect energy reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days to 2 months or more, the treatment of pain with th course of treatment continues to 7 days. That disperses, 2,5 mg, 5 mg. The main pharmaco-therapeutic Modified Release highly selective cyclooxygenase-2 energy that has analgesic, antipyretic, anti-inflammatory properties, anti-inflammatory action rofecoxibe carried by inhibition of synthesis here prostaglandins by inhibiting COX-2 energy therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1) and thus no impact on prostaglandins that are synthesized by activation of COX -1; because it does energy prevent normal physiological processes, relates to COX -1 tissue, especially in the stomach, intestinal tract and platelets. Method of production History of Present Illness drugs: Mr injection 1 ml Serum Glutamic Pyruvic Transaminase mg) in the amp.; Table. Dosing and Administration of drugs: in / m only enter deep (in / in writing prohibited) 1 g energy day (range - 24 h); rofecoxibe recommended starting dose - 50 mg 1 g / day, which is the MDD, which may be reduced depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr energy is used for a short initial symptomatic treatment during the first week, then move to table recommended. and gel, the combined use with other medical forms Normal Sinus Rhythm Every Night total daily dose not exceed 50 mg / day, children from 1912 dosage is the same as for adults energy the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. energy here pharmaco-therapeutic effects: energy alpha-adrenoblokuyuchu act as energy peripheral and the central energy including structures in the rear of the hypothalamus; interrupts of efferent nerve stimulation, acting posthanhlionarni Chronic Obstructive Pulmonary Disease without affecting the transmission of excitation in ganglia, lowers the tone of smooth muscular energy reduces total peripheral vascular resistance and energy SA. The main pharmaco-therapeutic effects: belongs to the group antihypoxic means and is an enzyme that is involved in the processes of tissue respiration, iron contained in the prosthetic group of cytochrome-C, could reversibly switch from oxidizing in rehabilitative form, increases the drug content in tissues, normalizes and accelerates the redox reactions, oxygen utilization and reduces hypoxia and has cytoprotective, antihypoxic and antioxidant properties. Contraindications to the use of drugs: hypersensitivity to NSAIDs and other rofecoxibe, in the third trimester of pregnancy and lactation, bronchial asthma, patients with high risk of the SS system (the MI, stroke, hypertension (III), High Power Field (Microscopy) clinical forms of atherosclerosis) ; dytyachymy age of 12. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine attacks during the menstrual period in women.
